早产前胎膜早破后产前糖皮质激素加强疗程:双盲随机试验
这项多中心、安慰剂对照双盲随机试验纳入194例孕24.0至32.9周、单胎、早产前胎膜早破且距首次产前糖皮质激素疗程至少7天的患者,比较加强疗程(倍他米松12 mg每24小时一次共2天)与生理盐水安慰剂。主要结局复合新生儿疾病或死亡在加强组64% vs 安慰剂组66%(OR 0.82,95%CI 0.43-1.57),无显著差异,母婴感染亦无差异。
要点
- 早产前胎膜早破后距首疗程至少7天给予加强糖皮质激素未改善新生儿结局。
- 主要结局加强组64% vs 安慰剂组66%,OR 0.82(95%CI 0.43-1.57),无显著差异。
- 加强疗程未增加绒毛膜羊膜炎、产后子宫内膜炎、伤口感染或新生儿败血症。
核心结论
- 在早产前胎膜早破患者中,首次产前糖皮质激素疗程至少7天后给予加强疗程未改善新生儿疾病或任何其他结局。
- 加强产前糖皮质激素未增加母体或新生儿感染。
研究设计与样本
- 多中心、安慰剂对照双盲随机临床试验,2016年4月至2022年8月共194例患者知情同意并随机(占411例合格患者的47%)。
- 纳入标准为早产前胎膜早破、孕24.0至32.9周、单胎、随机前至少7天已接受首次产前糖皮质激素疗程、计划期待管理。
- 按孕周分层随机接受加强产前糖皮质激素(倍他米松12 mg每24小时一次共2天)或生理盐水安慰剂。
- 主要结局为复合新生儿疾病或死亡;样本量194例按主要结局从安慰剂组60%降至产前糖皮质激素组40%计算,把握度80%、P<.05。
- 意向性分析纳入192例患者(2例安慰剂组患者离院,结局未知)。
主要发现
- 主要结局发生在接受加强产前糖皮质激素患者的64% vs 接受安慰剂患者的66%(OR 0.82;95%CI 0.43-1.57;孕周分层Cochran-Mantel-Haenszel检验)。
- 主要结局各独立组分及次要新生儿和母体结局在产前糖皮质激素组与安慰剂组间无显著差异。
- 绒毛膜羊膜炎(22% vs 20%)、产后子宫内膜炎(1% vs 2%)、伤口感染(2% vs 0%)、证实的新生儿败血症(5% vs 3%)在两组间无差异。
关键数值与推荐
- 美国妇产科医师学会认为当前证据不足以作出推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 2例安慰剂组患者离院,结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preterm prelabor rupture of membranes is a leading cause of preterm birth and is responsible for 18% to 20% of perinatal deaths in the United States. An initial course of antenatal corticosteroids has been shown to reduce morbidity and mortality in patients with preterm prelabor rupture of membranes. For patients who remain undelivered for 7 days or more after the initial course of antenatal corticosteroids, it is uncertain whether a booster course of antenatal corticosteroids reduces neonatal morbidity or increases the infection risk. The American College of Obstetricians and Gynecologists has concluded that the current evidence is insufficient to make a recommendation. OBJECTIVE: This study aimed to evaluate if a single booster course of antenatal corticosteroids improves neonatal outcomes after preterm prelabor rupture of membranes. STUDY DESIGN: We conducted a multicenter, placebo-controlled randomized clinical trial. The inclusion criteria were preterm prelabor rupture of membranes, gestational age of 24.0 to 32.9 weeks, singleton, initial antenatal corticosteroid course administered at least 7 days before randomization, and planned expectant management. Consenting patients were randomized in gestational age blocks to either receive booster antenatal corticosteroids (12 mg betamethasone every 24 hours for 2 days) or a saline placebo. The primary outcome was composite neonatal morbidity or death. A sample size of 194 patients was calculated to yield 80% power at P<.05 to detect a reduction in primary outcome from 60% in placebo group to 40% in antenatal corticosteroids group. RESULTS: From April 2016 through August 2022, 194 patients consented and were randomized (47% of 411 eligible patients). Intent-to-treat analysis was performed on 192 patients (2 placebo patients left hospital, outcomes unknown). The groups had similar baseline characteristics. The primary outcome occurred in 64% of patients who received booster antenatal corticosteroids vs in 66% of patients who received the placebo (odds ratio, 0.82; 95% confidence interval, 0.43-1.57; gestational age-stratified Cochran-Mantel-Haenszel test). Individual components of the primary outcome and secondary neonatal and maternal outcomes were not significantly different between the antenatal corticosteroids and placebo groups. Specifically, chorioamnionitis (22% vs 20%), postpartum endometritis (1% vs 2%), wound infections (2% vs 0%), and proven neonatal sepsis (5% vs 3%) were not different between the groups. CONCLUSION: A booster course of antenatal corticosteroids at least 7 days after the first antenatal corticosteroids course in patients with preterm prelabor rupture of membranes did not improve neonatal morbidity or any other outcome in this adequately-powered, double-blind randomized clinical trial. Booster antenatal corticosteroids did not increase maternal or neonatal infection.
引用
- Porreco R, Garite TJ, Combs CA, et al. Booster course of antenatal corticosteroids after preterm prelabor rupture of membranes: a double-blind randomized trial. Am J Obstet Gynecol MFM. 2023. PMID: 36796641. doi:10.1016/j.ajogmf.2023.100896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。